MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2024 International Congress

September 27-October 1, 2024. Philadelphia, PA.

View by Title View Sessions
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Distinguishing Parkinson’s disease from atypical Parkinsonian syndrome using multistage deep learning based on dopamine transporter imaging

    JS. Park, JY. Gwak (Busan, Republic of Korea)

  • Distress Tolerance in Patients with Tremor Disorders

    P. Sheehan, K. Pyle, M. Coleman, D. Sblendorio, D. Talkington, Y. Deng, A. Murray, A. Memon, N. Jasinski, M. Moreno-Escobar, J. Frey (Morgantown, USA)

  • Do differences in risk aversion and perceived social support contribute to gender disparities in deep brain stimulation utilization in Parkinson’s disease

    B. Heffernan, S. Sillau, M. Sleyster, M. Fullard (Aurora, USA)

  • Do Lower Doses of Botulinum Neurotoxin Type-A Offer a Longer Duration of Effect and Superior Efficacy in Patients with Cervical Dystonia?

    A. Kundrick, H. Fernandez (Cleveland, USA)

  • Do Proton Pump Inhibitors Increase the Risk of Parkinson’s Disease? A systematic review and meta-analysis

    S. Karki, A. Parajuli (Kathmandu, Nepal)

  • Does cannabis increase one’s risk for a fall in Parkinson’s disease?: cross-sectional analysis of self-report balance problems and freezing of gait

    M. Landers, A. Dockery, A. Hernandez, C. Miyashiro (Las Vegas, USA)

  • Dopa-responsive ataxia with compound heterozygous variants in MRE11

    A. Dugar, E. Levine, M. Barbosa, W. Tse (New York, USA)

  • Dopamine agonist use and psychotic symptoms in patients with Parkinson’s disease.

    D. Ortiz-Zacarias, S. Castillo-Torres, M. Cansino-Torres, J. Trejo-Ayala, B. Chávez-Luevanos, I. Estrada-Bellmann (Monterrey, Mexico)

  • Dopamine Dysregulation in Parkinson’s Disease and Substance Use: Therapeutic Use and Compulsive Behaviors Thin Line

    J. Hall, R. Islam, D. Nolasco, B. Carr (GAINESVILLE, USA)

  • Dopamine Dysregulation Syndrome Outcomes following Pallidal Deep Brain Stimulation in Parkinson’s Disease

    N. David, S. Factor, R. Tripathi, L. Higginbotham (Atlanta, USA)

  • « Previous Page
  • 1
  • …
  • 56
  • 57
  • 58
  • 59
  • 60
  • …
  • 181
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley